Talk about hitting the jackpot.
Gilead Sciences’ deal to acquire Immunomedics for about $21 billion, or $88 per share, was a huge, unexpected windfall for several hedge funds after shares of Immunomedics nearly doubled to $86.84 on Monday following the announcement.
At the end of the second quarter, the biopharma company’s stock was the seventh-largest-long U.S.
